title: Effect of continuous regional vasoactive agent infusion on liver metastasis blood flow.
abstract: Regionally administered vasopressors might increase tumour chemotherapy uptake by differentially constricting normal and tumour blood vessels, leading to a selective increase in blood flow to the tumour. In this study, we compared the effects of the vasopressors angiotensin II, vasopressin and endothelin I and the vasodilator calcitonin gene-related peptide (CGRP) by continuously measuring liver parenchymal and tumour blood flow during a 30-min regional vasoactive infusion in a rat HSN liver metastasis model. Vasopressin and angiotensin II produced a vasoconstriction that decreased despite continued infusion, while endothelin I infusion led to prolonged vasoconstriction with a more gradual onset. CGRP infusion resulted in increased vessel conductance but a reduction in blood flow due to systemic hypotension. The tumour to normal flow ratio (TNR) was transiently increased during infusion of all pressors, but only endothelin I produced sufficient change to result in a rise in average TNR throughout pressor infusion. Continuous liver and tumour blood flow measurement throughout vasoactive infusion demonstrated that the extent and the duration of blood flow change varied with the agents assessed. No vasoactive agent increased tumour blood flow, but endothelin I had the most suitable vasoactive properties for enhancing tumour uptake of continuously infused chemotherapy.
authors.affiliation: Department of Surgery, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK.
authors.forename: M J
authors.initials: MJ
authors.lastname: Dworkin
authors.forename: P
authors.initials: P
authors.lastname: Carnochan
authors.forename: T G
authors.initials: TG
authors.lastname: Allen-Mersh
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology; D004195:Disease Models, Animal; D019332:Endothelin-1 / Q000494:pharmacology; D007261:Infusions, Intra-Arterial / Q000379:methods*; D017078:Laser-Doppler Flowmetry; D008102:Liver Circulation / Q000187:drug effects*; D008113:Liver Neoplasms / Q000098:blood supply* / Q000556:secondary; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*; D014667:Vasopressins / Q000494:pharmacology
chemical_list: D019332:Endothelin-1; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D014667:Vasopressins; D000804:Angiotensin II; D015740:Calcitonin Gene-Related Peptide